Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 11/20 | 1.00 |
| ▸ | DUSP22 | Q9NRW4 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.61 |
| ▸ | DUSP26 | Q9BV47 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12637114 | 0.91 | CFTR (0.84) | CFTRDUSP22MEN1KMT2ANLRP3 | |
| SCHEMBL1327129 | 0.89 | CFTR (1.00) | CFTRDUSP22MEN1KMT2ANLRP3 | |
| SCHEMBL1888931 | 0.89 | CFTR (1.00) | CFTRDUSP22MEN1KMT2ANLRP3 | |
| SCHEMBL1882119 | 0.86 | CFTR (1.00) | CFTRDUSP22MEN1KMT2ANLRP3 | |
| SCHEMBL1882115 | 0.86 | CFTR (1.00) | CFTRDUSP22MEN1KMT2ANLRP3 | |
| SCHEMBL1882116 | 0.86 | CFTR (1.00) | CFTRDUSP22MEN1KMT2ANLRP3 | |
| SCHEMBL1882593 | 0.85 | CFTR (1.00) | CFTRDUSP22MEN1KMT2ANLRP3 | |
| SCHEMBL1882595 | 0.85 | CFTR (1.00) | CFTRDUSP22MEN1KMT2ANLRP3 | |
| SCHEMBL1882597 | 0.85 | CFTR (1.00) | CFTRDUSP22MEN1KMT2ANLRP3 | |
| SCHEMBL1326629 | 0.84 | CFTR (0.76) | CFTRDUSP22MEN1KMT2ANLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105565-A1 | WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105565-A1 | WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2009120803-A2 | WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105565-A1 | WATER SOLUBLE SMALL MOLECULE INHIBITORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, PKD1, PKD2 | CFTR 1/4885DUSP22 3990/4885MEN1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.